

Special Issue

Emerging Trends in the Study of Inherited Metabolic Disorders

Message from the Guest Editor

Inherited metabolic disorders (IMDs) are a diverse group of genetic conditions that disrupt normal metabolic processes, leading to severe and often life-threatening health issues. Recent advancements in molecular biology, genetics, and biotechnology have revolutionized our understanding of these disorders, paving the way for novel diagnostic and therapeutic strategies. This Special Issue aims to provide a comprehensive overview of the latest research and emerging trends in the study of IMDs. We invite original research articles, reviews, and case studies that explore innovative approaches to understanding the molecular and genetic bases of IMDs, including new insights into disease mechanisms and pathways. Topics of interest include, but are not limited to, the development and application of advanced model systems (such as genetically modified mouse models and patient-derived organoids), gene therapy techniques, and cutting-edge diagnostic tools. Additionally, studies investigating the interplay between metabolic disorders and other conditions, such as cancer, and the exploration of potential biomarkers for early detection and prognosis are highly encouraged.

Guest Editor

Dr. Sudeep Gautam

Unit on Skeletal Genomics, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD 20892, USA

Deadline for manuscript submissions

31 August 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/212926

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).